Stuff:
Thursday September 23, 6:00 am Eastern Time
Company Press Release
SOURCE: Front Line Strategic Management Consulting, Inc.
Opportunities for Gene Therapy Vary Among Cancer, Cardiovascular, HIV And Monogenic Disorders
FOSTER CITY, Calif., Sept. 23 /PRNewswire/ -- Worldwide sales for the gene therapy market is expected to reach a total of $4.8 million by 2008. Gene therapy products in development primarily target cancer, with a lower emphasis on HIV, cardiovascular, cystic fibrosis, hemophilia A and Gaucher's disease. Future trends impacting the market include re-emphasis on basic research, evaluation of human clinical trial data, easing of safety restrictions, use of replication-competent viruses and germline gene therapy according to a new study published by Front Line Strategic Management Consulting, Inc.
Over 60% of the gene therapy clinical trials currently taking place are targeting cancer. Some of the institutions in phase II development include Therion Biologics, Introgen, Targeted Genetics, Nagoya University, Genzyme, NCI and Virogenetics. The four largest indications under investigation are breast, colon, lung and prostate cancer, which make up 53% of the total worldwide cancer population.
The cardiovascular disease segment is expected to grow at the fastest rate due to the strong clinical data resulting from CVD's good fit with gene therapy technology. The increase in market size can be attributed to the growth of patient populations who suffer from atherosclerosis and hypertension/aortic stenosis.
Gene therapy has the opportunity to capture part of the $2.13 billion spent on AIDS and AIDS-related drugs and could cause the market to expand further. Gene therapy products for HIV are not expected until 2004. Subsequent sales are estimated to reach $142 million in 2008.
Companies that will contribute to revenue growth in gene therapy include Canji (Schering-Plough), Cell Genesys, Chiron Viagene, Collateral Therapeutics, Genetic Therapy/Systemix, Onyx Pharmaceuticals, Oxford Biomedica, RPR Gencell, Valentis and Vical.
Front Line Strategic Management Consulting, Inc., is a strategy and market consultancy specializing in the pharmaceutical and biotechnology industries, providing clients with strategic evaluations, recommendations and competitive assessments. This research was obtained and analyzed in its 1999 report, Gene Therapy, A Strategic Business Analysis. Executive summaries of all Front Line reports are available to press at no charge. Industry participants may request report outlines.
SOURCE: Front Line Strategic Management Consulting, Inc.
--------------------------------------------------------------------------------
DAK |
